Déjà Vu All Over Again: Senate Democratic Appropriators Restore Family Planning Policy and Increase Funding, Countering House Republican Cuts and Anti-SRHR “Riders”

Powering our global movement through activism, representation and accountability. Read more: Annual Report
This update outlines what you need to know about the court case attacking access to mifepristone, one of two drugs most commonly used in medication abortion in the United States, as of March 10, 2023. It describes what has happened and what is at stake if the FDA approval for mifepristone is rescinded. This update also outlines potential implications globally and provides clear and actionable next steps to learn more about this case and monitor similar threats to abortion access.
Stay informed about the issues impacting sexual and reproductive health and rights.